Back To: Home

September 27 - October 4, 2014
Short Course on Systems Genetics - The Jackson Laboratory, Bar Harbor ME

September 28 - October 3, 2014
FACSS SCIX 2014 - Grand Sierra Resort, Reno-Tahoe, Nevada

More Events

Pushing lower boundaries
by Randall C. Willis  |  Email the author

GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study that will evaluate preliminary pharmacokinetics (PK) and metabolism of five compounds. Xceleron will conduct clinical trials in Europe with accelerator mass spectrometry analysis completed at the company's GLP accredited laboratories in York, U.K.
"Partnering with Xceleron to bring our drug candidates into clinical development early in the development process provides Neurocrine with significant benefits in terms of or additional candidate selection as well as reduced risk and cost," said Dr. Haig Bozigian, Neurocrine's vice president of preclinical development. "While our lead compound is being evaluated in clinical studies, microdose studies will provide additional valuable comparative pharmacokinetics and bioavailability for our back-up compounds."


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.